Neko Health — Consumer Multi-Sensor Full-Body Scan
Insufficient evidence / under studyDgradePlausibility · PlausibleSensing Physics
Neko's hardware is genuine: a single visit combines thermal imaging, 3D body/skin scanning, ECG, laser/optical and finger sensors, and blood tests, generating millions of data points per session. What is missing is outcome evidence — no randomized trial shows that scanning asymptomatic, healthy people improves survival or other hard outcomes, and broad screening of the well carries a real risk of overdiagnosis and false positives. The brand is best read as an example of the consumer-full-body-scan class, which sits in the under-study / sensing-overreach tier: real instruments, an unproven population-screening claim.
Origin & lineage
Neko Health is a Stockholm-founded preventive-health startup co-founded by Spotify's Daniel Ek and Hjalmar Nilsonne, offering an hour-long multi-sensor body scan in dedicated clinics.
Claimed mechanism
The scan fuses multiple real sensing modalities — thermal cameras, 3D optical/laser surface scanning, ECG, finger sensors and blood biomarkers — to map cardiovascular, metabolic and skin signals. The implied claim is that periodically scanning healthy people catches disease early and thereby improves long-term outcomes.
Plausibility
Plausible–weak, early/under study — the sensors measure real signals, but the leap from 'we can measure many things' to 'screening the asymptomatic improves outcomes' is unproven.
Evidence — grade D
Graded D because there is no outcome RCT: published Neko data are single-arm detection-rate reports, not controlled evidence that scanning the asymptomatic changes mortality or morbidity. The screening benefit is unproven, and guideline bodies (e.g. the American College of Radiology) advise against whole-body screening of asymptomatic people, citing low yield of treatable disease and high false-positive/overdiagnosis burden.
Cross-reference
An overreach cousin of AngioCode and CGM-as-longevity (real sensors, oversized population-health claims), and the inverse of MESI — a validated single-purpose diagnostic — which shows what bounded, evidence-backed use of a sensor looks like.
Market
Makers: Neko Health (Stockholm), cited here as one example of the consumer full-body-scan class. Models: Clinic-based multi-sensor full-body scan (thermal, 3D/laser optical, ECG, finger sensors, bloods); ~50–60 minute session. Price: Reported at about £299–£300 per scan in the UK; the company raised a $260M Series B at a ~$1.8B valuation (Jan 2025) to fund US/Europe expansion.
Kernel — keep vs set aside
Keep — real substrate
Keep the genuine instrumentation — thermal imaging, 3D/optical-laser surface mapping, ECG, finger sensors and standard blood biomarkers — which are real, established measurements with legitimate diagnostic uses in the right context.
Set aside — claim
Set aside the unproven 'scan-the-healthy-and-live-longer' screening claim: absent outcome trials, routinely scanning asymptomatic people has not been shown to improve outcomes and predictably generates incidental findings, false positives and overdiagnosis.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
Not specified in source; US market entry and any device clearance pending as the company expands into the United States.